Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative therapies function by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to meals. By activating GLP-1 receptors retatrutide in the pancreas, these compounds enhance insulin secretion and in

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing differences in their pha